SOURCE: Chembio Diagnostics, Inc.

November 15, 2005 09:00 ET

Chembio Adds Expertise in Tuberculosis and Global Health to Advisory Board

MEDFORD, NY -- (MARKET WIRE) -- November 15, 2005 -- Chembio Diagnostics, Inc. (OTC BB: CEMI) is pleased to announce that Mr. Allen Moore and Dr. Peter Andersen have each agreed to serve on the Company's Advisory Board. Advisory Board members are individuals who have held leadership positions in the public or private sector relating to diagnostics or global health policy and who support Chembio's goal of ensuring sustainable supplies of simple, accurate, cost-effective rapid tests to all those who need them.

Mr. Moore is currently a Senior Fellow with the Global Health Council, the world's largest membership alliance dedicated to saving lives by improving health throughout the world. Previously he served as Deputy Chief of Staff and Policy Director for Senate Majority Leader Bill Frist. Mr. Moore's vast experience in public and global health policy comes from years of leadership in the legislative and executive branches of the United States government. His other appointments include serving as Under Secretary of Commerce for President Reagan and as Associate Director of President Ford's White House domestic policy staff.

Dr. Peter Andersen is currently Vice President of Vaccine Research and Development at Statens Serum Institut in Copenhagen, Denmark, a highly recognized international research institution whose goal is to control and prevent the spread of infectious diseases and biological threats. Dr. Andersen brings exceptional expertise to Chembio's ongoing efforts to develop a rapid diagnostic test for Tuberculosis (TB). There is a huge unmet need for this test, TB being the leading cause of death in HIV-infections. His research has focused on the identification and characterization of novel antigens and immune mechanisms for protection against this disease and he has more than one hundred keynote presentations and papers to his credit.

The Company also announced that Mr. Les Stutzman has recently joined Chembio as Vice President of Marketing to help lead the development and launch of rapid tests for veterinary and human TB. Mr. Stutzman, who has Masters degrees in both Microbiology and Business Administration has spent over twenty years in marketing positions with leading diagnostics companies, including Global Director for Microbiology and Business Development at Biomerieux, Inc., (formerly Organon Teknika Corp.), Durham, North Carolina.

"We are delighted to have individuals of such distinction and expertise guide Chembio," said Larry Siebert, Chairman and President of Chembio. "We have an outstanding team of executives and advisors helping build Chembio's long term value."

Chembio's rapid HIV tests include the HIV 1/2 Stat-Pak™, HIV 1/2 Stat-Pak Dipstick™ and the HIV 1/2 Sure Check™. These tests are simple, safe, cost-effective and operator-friendly requiring less than five micro liters of whole blood from a finger-stick.


For more information about the Staten Serum Institut, please visit


For more information about the Global Health Council, please visit


Chembio Diagnostics, Inc. (Chembio) possesses expertise in the development and manufacturing of rapid test products for various infectious diseases, including HIV, Tuberculosis and Chagas Disease. References to Chembio Diagnostics, Inc. may actually refer to Chembio Diagnostic Systems, Inc.; the 100%-owned subsidiary of Chembio Diagnostics, Inc. Chembio is located at 3661 Horseblock Road, Medford, NY 11763.


Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. Forward-looking statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to Chembio's ability to obtain additional financing and the demand for Chembio's products. Chembio undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in Chembio's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact Chembio's success are more fully disclosed in Chembio's most recent public filings with the U.S. Securities and Exchange Commission.

Contact Information